Liquidia (NASDAQ:LQDA – Get Free Report) had its target price hoisted by Wells Fargo & Company from $33.00 to $40.00 in a report issued on Wednesday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential downside of 25.06% from the stock’s current price.
Other research analysts also recently issued research reports about the stock. Citigroup reiterated a “neutral” rating on shares of Liquidia in a research note on Thursday, October 1st. Royal Bank Of Canada set a $65.00 price objective on shares of Liquidia in a research report on Thursday, October 15th. Raymond James Financial upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $53.00 to $77.00 in a report on Wednesday. Wedbush set a $58.00 price objective on shares of Liquidia in a research report on Friday, October 2nd. Finally, BTIG Research boosted their target price on shares of Liquidia from $70.00 to $87.00 and gave the stock a “buy” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $77.31.
Get Our Latest Stock Analysis on LQDA
Liquidia Stock Up 3.8%
LQDA stock traded up $1.98 during mid-day trading on Wednesday, reaching $53.38. The company had a trading volume of 419,501 shares, compared to its average volume of 2,282,673. The firm has a fifty day simple moving average of $49.65 and a 200 day simple moving average of $54.53. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The company has a market capitalization of $4.78 billion, a price-to-earnings ratio of 39.05, a price-to-earnings-growth ratio of 0.42 and a beta of 0.40. Liquidia has a fifty-two week low of $22.31 and a fifty-two week high of $93.61.
Liquidia (NASDAQ:LQDA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($2.64) EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($3.60). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $225.30 million for the quarter, compared to analyst estimates of $214.18 million. During the same period in the prior year, the firm posted ($0.04) earnings per share. The business’s quarterly revenue was up 314.9% compared to the same quarter last year. Analysts forecast that Liquidia will post 2.05 earnings per share for the current fiscal year.
Insider Buying and Selling at Liquidia
In related news, General Counsel Russell Schundler sold 13,692 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $389,948.16. Following the completion of the transaction, the general counsel directly owned 602,841 shares of the company’s stock, valued at $17,168,911.68. This represents a 2.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jason Adair sold 688 shares of the stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $43.19, for a total transaction of $29,714.72. Following the completion of the transaction, the insider owned 177,269 shares in the company, valued at $7,656,248.11. This represents a 0.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 566,579 shares of company stock worth $25,746,120. 25.60% of the stock is currently owned by corporate insiders.
Institutional Trading of Liquidia
Several institutional investors have recently modified their holdings of LQDA. Pinnacle Wealth Planning Services Inc. grew its position in shares of Liquidia by 26.2% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,557 shares of the company’s stock valued at $47,000 after buying an additional 323 shares during the last quarter. Globeflex Capital L P purchased a new stake in Liquidia in the second quarter valued at $175,000. Nykredit A S purchased a new stake in Liquidia in the second quarter valued at $177,000. Sterling Capital Management LLC lifted its position in Liquidia by 839.1% in the third quarter. Sterling Capital Management LLC now owns 2,329 shares of the company’s stock valued at $70,000 after acquiring an additional 2,081 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Liquidia by 13.8% in the third quarter. Nisa Investment Advisors LLC now owns 2,634 shares of the company’s stock valued at $80,000 after acquiring an additional 320 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.
More Liquidia News
Here’s some of the latest news about LQDA:
- Positive Sentiment: Third-quarter revenue was $225.3 million, up 314.9% year over year and above consensus. YUTREPIA sales reached $222.7 million, highlighting strong commercial momentum. Liquidia third-quarter results
- Positive Sentiment: Reports said litigation was resolved, removing a potential source of uncertainty for investors. Results and litigation update
- Positive Sentiment: Analysts raised targets: Raymond James upgraded LQDA to “strong-buy” and lifted its target to $77 from $53; Needham raised its target to $66 from $58, maintaining “buy”; BTIG increased its target to $87 from $70, also maintaining “buy.” These revisions signal improved analyst optimism. Raymond James rating information
Liquidia Company Profile
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.
Featured Articles
- Five stocks we like better than Liquidia
- Alphabet Escalates AI Chip Rivalry With NVIDIA
- Amazon’s Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?
- 3 Stocks Wall Street Likes More Than the Market Does
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
